Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The court found that the plaintiffs’ claims were unsustainable because the underlying patent litigation was not objectively baseless and did not constitute sham litigation. The court had previously granted Watson’s motion to dismiss all claims asserted by the Federal Trade Commission concerning the same settlement.
Featured News
Meta Hit With $25 Billion Penalty Over Facebook Privacy Claims
Oct 21, 2026 by
CPI
Keurig Faces Antitrust Trial After Federal Court Rejects Legal Challenge
Oct 21, 2026 by
CPI
Spain Opens Antitrust Investigation Into Exolum Over Pricing and Market Access
Oct 21, 2026 by
CPI
OpenAI Strikes Google Cloud Deal in Push Beyond Microsoft
Oct 21, 2026 by
CPI
Getty Images Files for Bankruptcy as $533M Restructuring Paves Way for Private Ownership
Oct 21, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI
In Praise of Theories of Benefits
Oct 19, 2026 by
Cyril Hariton & Pierre Regibeau
Closing the Efficiencies Gap
Oct 19, 2026 by
Kasia Czapracka & Marika Harjula
Analysis of Dynamic Trade-Offs Under the New Guidelines: Would Cases Like Amazon/Irobot Turn Out Differently?
Oct 19, 2026 by
Oliver Latham, Sam Marden, Saul Mendelsohn & Serge Moresi
Exploitative Portfolio Effects In EU Merger Control: From Mars/Kellanova to the Draft Merger Guidelines
Oct 19, 2026 by
Niels Baeten, Danette Chan & Elizabeth Malik